IBDEI1ER ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22521,2)
 ;;=^5151292
 ;;^UTILITY(U,$J,358.3,22522,0)
 ;;=Z20.5^^102^1141^49
 ;;^UTILITY(U,$J,358.3,22522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22522,1,3,0)
 ;;=3^Contact w/ & Suspected Exposure to Viral Hepatitis
 ;;^UTILITY(U,$J,358.3,22522,1,4,0)
 ;;=4^Z20.5
 ;;^UTILITY(U,$J,358.3,22522,2)
 ;;=^5062767
 ;;^UTILITY(U,$J,358.3,22523,0)
 ;;=M79.10^^102^1141^162
 ;;^UTILITY(U,$J,358.3,22523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22523,1,3,0)
 ;;=3^Myalgia
 ;;^UTILITY(U,$J,358.3,22523,1,4,0)
 ;;=4^M79.10
 ;;^UTILITY(U,$J,358.3,22523,2)
 ;;=^5157394
 ;;^UTILITY(U,$J,358.3,22524,0)
 ;;=K65.9^^102^1141^185
 ;;^UTILITY(U,$J,358.3,22524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22524,1,3,0)
 ;;=3^Peritonitis,Bacterial,Unspec
 ;;^UTILITY(U,$J,358.3,22524,1,4,0)
 ;;=4^K65.9
 ;;^UTILITY(U,$J,358.3,22524,2)
 ;;=^5008777
 ;;^UTILITY(U,$J,358.3,22525,0)
 ;;=B95.62^^102^1141^153
 ;;^UTILITY(U,$J,358.3,22525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22525,1,3,0)
 ;;=3^MRSA
 ;;^UTILITY(U,$J,358.3,22525,1,4,0)
 ;;=4^B95.62
 ;;^UTILITY(U,$J,358.3,22525,2)
 ;;=^5000842
 ;;^UTILITY(U,$J,358.3,22526,0)
 ;;=Z21.^^102^1142^42
 ;;^UTILITY(U,$J,358.3,22526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22526,1,3,0)
 ;;=3^HIV+ Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,22526,1,4,0)
 ;;=4^Z21.
 ;;^UTILITY(U,$J,358.3,22526,2)
 ;;=^5062777
 ;;^UTILITY(U,$J,358.3,22527,0)
 ;;=B20.^^102^1142^41
 ;;^UTILITY(U,$J,358.3,22527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22527,1,3,0)
 ;;=3^HIV+ (Symptomatic)/AIDS
 ;;^UTILITY(U,$J,358.3,22527,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,22527,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,22528,0)
 ;;=Z23.^^102^1142^30
 ;;^UTILITY(U,$J,358.3,22528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22528,1,3,0)
 ;;=3^Encounter for Immunization
 ;;^UTILITY(U,$J,358.3,22528,1,4,0)
 ;;=4^Z23.
 ;;^UTILITY(U,$J,358.3,22528,2)
 ;;=^5062795
 ;;^UTILITY(U,$J,358.3,22529,0)
 ;;=Z20.828^^102^1142^18
 ;;^UTILITY(U,$J,358.3,22529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22529,1,3,0)
 ;;=3^Contact/Exposure to Viral Diseases
 ;;^UTILITY(U,$J,358.3,22529,1,4,0)
 ;;=4^Z20.828
 ;;^UTILITY(U,$J,358.3,22529,2)
 ;;=^5062774
 ;;^UTILITY(U,$J,358.3,22530,0)
 ;;=Z77.21^^102^1142^17
 ;;^UTILITY(U,$J,358.3,22530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22530,1,3,0)
 ;;=3^Contact/Exposure to Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,22530,1,4,0)
 ;;=4^Z77.21
 ;;^UTILITY(U,$J,358.3,22530,2)
 ;;=^5063323
 ;;^UTILITY(U,$J,358.3,22531,0)
 ;;=Z72.51^^102^1142^58
 ;;^UTILITY(U,$J,358.3,22531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22531,1,3,0)
 ;;=3^High Risk Sexual Behaviors
 ;;^UTILITY(U,$J,358.3,22531,1,4,0)
 ;;=4^Z72.51
 ;;^UTILITY(U,$J,358.3,22531,2)
 ;;=^5063258
 ;;^UTILITY(U,$J,358.3,22532,0)
 ;;=Z79.899^^102^1142^68
 ;;^UTILITY(U,$J,358.3,22532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22532,1,3,0)
 ;;=3^Long Term Use of Medications
 ;;^UTILITY(U,$J,358.3,22532,1,4,0)
 ;;=4^Z79.899
 ;;^UTILITY(U,$J,358.3,22532,2)
 ;;=^5063343
 ;;^UTILITY(U,$J,358.3,22533,0)
 ;;=A06.9^^102^1142^2
 ;;^UTILITY(U,$J,358.3,22533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22533,1,3,0)
 ;;=3^Amebiasis
 ;;^UTILITY(U,$J,358.3,22533,1,4,0)
 ;;=4^A06.9
 ;;^UTILITY(U,$J,358.3,22533,2)
 ;;=^5000048
 ;;^UTILITY(U,$J,358.3,22534,0)
 ;;=K60.2^^102^1142^3
 ;;^UTILITY(U,$J,358.3,22534,1,0)
 ;;=^358.31IA^4^2
